Johnson & Johnson will report its Q2 2017 earnings on July 18. The company’s pharmaceutical business disappointed investors in the first quarter as growth stalled due to pricing issues and competitive pressure.
from Forbes Real Time http://www.forbes.com/sites/greatspeculations/2017/07/14/johnson-johnsons-near-term-growth-likely-to-remain-subdued/
via IFTTT
No comments:
Post a Comment